Oppenheimer cuts Prothena stock rating after trial setback

Oppenheimer downgraded Prothena (PRTA) from Outperform to Perform, removing its price target, after the Phase 3 AFFIRM-AL trial for birtamimab failed to meet primary and key secondary endpoints, leading to the discontinuation of the drug's development and significant cost-cutting measures; the failure prompted Jefferies to also downgrade the stock, while other firms lowered price targets but maintained positive ratings, citing the company's financial stability and ongoing programs, including PRX012 for Alzheimer's, with upcoming clinical readouts expected.

Analysis

Prothena Corp (NASDAQ:PRTA) has experienced a critical setback with its lead drug candidate, birtamimab, failing to meet the primary endpoint of all-cause mortality (hazard ratio 0.915) and key secondary endpoints in the Phase 3 AFFIRM-AL trial for AL amyloidosis, leading to the discontinuation of its development. This pivotal failure has triggered significant cost-cutting measures, including planned workforce reductions, and prompted Oppenheimer to downgrade PRTA stock from Outperform to Perform, removing its price target, while Jefferies also downgraded to Hold, cutting its price target from $32 to $6. The stock has declined 67% over the past year, trading at $6.58 with a market capitalization of $354 million. However, Prothena possesses financial resilience, evidenced by a current ratio of 9.0, minimal debt-to-equity at 0.02, and Q1 2025 cash reserves of approximately $420 million, guiding for around $300 million by year-end. Investor focus now shifts to the remaining pipeline, particularly PRX012 for Alzheimer's, which showed early promise and expects Phase 1 results in August, and updates from collaborations with Roche, Novo Nordisk, and Bristol Myers Squibb. Despite the birtamimab disappointment, some analysts maintain positive ratings, albeit with lowered price targets (e.g., H.C. Wainwright Buy, PT $30; Citizens JMP Market Outperform, PT $78), contributing to a broader analyst consensus of 1.9, while InvestingPro's Fair Value model indicates the stock is slightly undervalued. A comprehensive strategic update, including revised financial guidance, is expected from management in June.

Key Decisions for Investors

• Investors should closely monitor Prothena's strategic update in June and Phase 1 results for PRX012 in August, as these are critical catalysts for reassessing the company's prospects following the birtamimab failure.
• Evaluate the current stock valuation in light of the significant price decline and Prothena's robust cash position, balanced against the considerable clinical development risks associated with its remaining, predominantly early-stage, pipeline assets.
• Maintain a cautious stance, focusing on the company's ability to effectively implement cost-cutting measures and advance its other programs, particularly given the wide divergence in analyst price targets which underscores the prevailing uncertainty.